Bindkin Bio is a biotechnology startup founded in 2018 and headquartered in the United States. The company specializes in providing high-throughput, real-time binding kinetics data for various drug discovery purposes. Its slogan "Binding Kinetics in Real Time" emphasizes its core competency.
Bindkin Bio serves as a Contract Research Organization (CRO), supporting clients' drug discovery endeavors by supplying experimental data crucial for computational drug-target predictions. This capacity positions the company at the intersection of biotechnology, pharmaceuticals, and data-driven drug development.
As of now, there is no public information available on the company's last investment or its associated investors. While Bindkin Bio operates in a niche yet critical segment of the biotechnology industry, attracting investor interest could be essential for scaling its operations and staying ahead in the competitive drug discovery landscape.
There is no investment information
No recent news or press coverage available for Bindkin Bio.